Cytocares Inc

This early-phase study tests a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that hasn't responded to standard treatments. The main goal is to check safety and find the right dose, with a secondary look at whether it helps control the diseas…

This early-stage study is testing an experimental drug called CC312 in people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 44 a…

This early-stage study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus or rheumatoid arthritis that haven't responded to standard treatments. CC312 is designed to help the body's immune cells target and destroy faulty B cells tha…

This early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to check safety and how the body handles the drug, not to cure the disease. Participants will receive either CC312 or a placebo, and researchers will monitor side eff…